Management of cardiovascular risk factors in people with diabetes in primary care: Cross-sectional study

Public Health

Volumn 120, Issue 7, 2006, Pages 654-663

  Petri, Alide ^a   de Lusignan, Simon ^b   Williams, John ^c   Chan, Tom ^d   Majeed, Azeem ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d SURREY AND BORDERS PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiovascular risk factors; Diabetes mellitus; Primary health care; Sex inequalities

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

CARDIOVASCULAR DISEASE; DIABETES; DISEASE PREVALENCE; HEALTH RISK; MORBIDITY; MORTALITY; PRIMARY HEALTH CARE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DATA ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; GENERAL PRACTICE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; ORGANIZATION; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; RISK MANAGEMENT; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; ENGLAND; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 33745676613     PISSN: 00333506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.puhe.2006.03.010     Document Type: Article

References (30)

1. Garcia M., McNamara P., Gordon T., and Kannel W. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up. Diabetes 23 (1974) 105-111
2. Stamler J., Vaccaro O., Neaton J., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diab Care 16 (1993) 434-444
3. Sawicki P., and Berger M. Prognosis and treatment of cardiovascular disease in diabetes mellitus. J Clin Basic Cardiol 2 (1999) 22-33
4. Chun B., Dobson A., and Heller R. The impact of diabetes on survival among patients with first myocardial infarction. Diab Care 20 (1997) 704-708
5. Stevens R., Coleman R., Adler A., Straton I., Matthews D., and Holman R. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diab Care 27 (2004) 201-207
6. Department of Health. National service framework for diabetes: standards (2001), Department of Health, London, UK
7. McIntosh A., Hutchinson A., Feder G., Durrington P., Elkeles R., Hitman G., et al. Clinical guidelines for type 2 diabetes. Lipid management. School of Health and Related Research (2002), University of Sheffield, Sheffield, UK
8. National Institute for Clinical Excellence. Management of type 2 diabetes. Management of blood pressure and blood lipids (2002), National Institute for Clinical Excellence, London, UK
9. Hutchinsin A., McIntosh A., Griffiths C., Amiel S., Bilous R., Chaturvedi N., et al. Clinical guidelines for type 2 diabetes. Blood pressure management. School of Health and Related Research (2002), University of Sheffield, Sheffield, UK
10. Williams B., Poulter N., Brown M., Davis M., McInnes G., Potter F., et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 (BHS IV). J Hum Hypertens 18 (2004) 139-185
11. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000) 412-419
12. Stratton I., Adler A., Neil H., Matthews D., Manley S., Cull C., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
13. Collins R., Armitage J., Parish S., Sleigh P., Peto R., and Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
14. Vijan S., and Hayward R. Pharmacological lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 140 (2004) 650-659
15. Ferrara A., Williamson D.F., Karter A.J., Thompson T.J., Kim C., and for the TRIAD Study Group. Sex differences in quality of health care related to ischemic heart disease prevention in patients with diabetes: the translating research into action for diabetes (TRIAD) study, 2000-2001. Diab Care 27 (2004) 2974-2976
16. Haffner S.M., Lehto S., Ronnema T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
17. Carroll K., Majeed A., Firth C., and Gray J. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J Public Health Med 25 (2003) 29-35
18. Brady A., Oliver M., and Pittard J. Secondary prevention in 24 431 patients with coronary heart disease: survey in primary care. BMJ 322 (2001) 1463
19. Hippisley-Cox J., Pringle M., Crown N., Meal A., and Wynn A. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 322 (2001) 832
20. Bowker T.J., Clayton T.C., Ingham J., McLennan N.R., Hobson H.L., Pyke S.D., et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 75 (1996) 334-342
21. NHS Health and Social Care Information Centre. Department of health: compendium of clinical and health indicators 2002. [URL: http://www.nchod.nhs.uk/NCHOD/HomeDb2R6.nsf/0/9C3DC66F78442BDC80256D0100 626C24]
22. Clinical Information Consultancy. MIQUEST-Morbidity Information Query and Export Syntax. [URL: http://www.clinical-info.co.uk/miquest.htm] [Au?1].
23. NHS and University of York. Yorkshire & humber public health observatory. [URL: http://www.yhpho.org.uk]
24. Forouhi N.G., Merrick D., Goyder E., Ferguson B.A., Abbas J., Lachowycz K., et al. Diabetes prevalence in England, 2001-estimates from an epidemiological model. Diabet Med 23 (2005) 189-197
25. STATA version 8.2. Stata Corporation, Texas, USA; 2003.
26. Newham N., Ryan R., Khunti R., and Majeed A. Prevalence of diagnosed diabetes mellitus in general practice in England and Wales, 1994 to 1998. Health Stat Q 14 (2002) 5-13
27. Hippisley-Cox J., and Pringle M. Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet 363 (2004) 423-428
28. National Centre for Social Research, Department of Epidemiology and Public Health, and Royal Free and University College Medical School. Health survey for England 2003 (2004), Department of Health, London, UK
29. Lusignan S., Sismanidis C., Carey I.M., DeWilde S., Richards N., and Cook D.G. Trends in the prevalence and management of diagnosed type 2 diabetes 1994-2001 in England and Wales. BMC Fam Pract 6 (2005) 13
30. DeWilde S., Carey I.M., Bremner S.A., Richards N., Hilton S.R., and Cook D.G. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?. Heart 89 (2003) 417-421